Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%R&D, TherapeuticsA combination of Moderna’s melanoma vaccine and Merck’s immunotherapy Keytruda cut the risk of skin cancer’s recurrence or death by 44% compared with Keytruda alone in a mid-stage trial. Read more December 13, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/06/Moderna-to-start-final-testing-stage-of-coronavirus-vaccine-in-July-Reuters-6-11-20.jpeg 280 370 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-12-13 08:58:362022-12-13 09:14:11Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%
